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Abstract
Background: The psychostimulant methylphenidate (MPH) is the first choice of drug treatment in Attention-Deficit/
Hyperactivity Disorder (ADHD). Since therapy often begins at a time when the brain is still developing and the
long-term consequences of MPH are still not fully clarified, we examined the influences of an acute treatment with
MPH on the differentiation and proliferation of murine neural stem cells (mNSC).
Findings and conclusion: We found that MPH enhanced neuronal differentiation and inhibited neural proliferation.
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Findings
Background
ADHD is one of the most frequent psychiatric disorders
in children and adolescents, with up to 5% affected world-
wide and similar prevalence rates throughout different
cultural settings [1,2]. It is characterized by developmentally
inappropriate levels of inattention, hyperactivity, and/or
impulsivity. These core symptoms lead to impairment in
home, school, and peer contexts. Stimulants, particularly
MPH, are part of the first-line treatment therapies for
ADHD [3] and in recent years, the number of prescriptions
has increased nearly tenfold [4]. Mechanistically, MPH is a
high-affinity inhibitor of the dopamine transporter and a
middle-affinity inhibitor to the norepinephrine transporter
[5]. However, given the extent of the prescribed use of
MPH [6] exposure to MPH during the early stages of brain
development raises some concern for public health due to
possible adverse long-term effects such as neurogenesis,
neuronal development, or receptor density. It is not clear
whether such changes occur; if they do, whether they are
related to medication or to the condition itself; if they are
caused by medication, whether they have functional signifi-
cance; and whether any changes are helpful or harmful to
mental development. Still, the full mechanism of action of
MPH has not yet been elucidated. A recent study by Lee
and colleagues (2012) investigated in vivo the effect of
chronically treatment of MPH on cell proliferation and
neuronal differentiation in adolescent mice brain tissue [7].
They could demonstrate that 10 mg/kg MPH treatment for
28 days enhances cell proliferation as well as neuroblast
differentiation in contrast to Lagace and colleagues (2006),
who detected an inhibition of survival of adult-generated
neurons in the temporal hippocampus of adolescent rats
after 16 days treatment with 2 mg/kg of MPH [8]. In
concern to the contrasting results and experimental designs
of in vivo studies, we investigated the in vitro effect of an
acute treatment with MPH using murine neural stem cells
(mNSC) originating from hippocampal tissue of embryonic
mice E15. NSC are neurosphere-forming cells and can
serve as a model for basic neurodevelopmental processes as
well as a potential source of neurodegenerative disease [9].
They are clonogenic, self-renewing, and multipotent cells
with plasticity to proliferate and to differentiate into all cell
types of the central nervous system (CNS) such as glia/as-
trocytes, oligodendrocytes, and neurons [10]. Such a model
enables the study of neuronal development, differentiation,
and neuronal cell death mechanisms in vitro.
Material and methods
Murine neural stem cell (mNSC) sphere culturing
mNSCs were derived from the hippocampus tissue of
albino mouse (Charles River, Japan) embryos on embryonic
day 15. Cells were cultured in a medial hormone mix
(MHM) with 10 μg/ml epidermal (EGF; Sigma aldrich,
Japan, Cat-No: SRP3196) and 10 μg/ml basic fibroblast
growth factors (bFGF; Sigma aldrich, Japan, Cat-No: F5392)
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for six days at 37°C and 5% CO2. After six days, the
grown NSC spheres were harvested and prepared for
differentiation and/or proliferation studies (for methods,
see below).
Differentiation study
mNSC spheres were collected and plated on a 30 μg/ml
poly-l-lysine (Sigma aldrich, Japan, Cat-No: P1274) and 20
μg/ml laminine (Invitrogen, Japan, Cat-No: 23017–015)
coated 8-well glass cover-slip and incubated for another 4
days. Each well had a final concentration of 22.8x104
cells/ml cultured in MHM containing 1% fetal bovine
serum (FBS) and without EGF and bFGF. The cells were
treated directly after seeding to the cover-slip using different
concentration (0 nM, 1 nM, 10 nM, 100 nM) of methyl-
phenidate (MPH; Sigma aldrich, Japan, Cat-No: M2892).
On the last day, cells were fixed with 4% paraformalde-
hyde (Fluka, Japan, Cat-No: 76240) for 20 minutes at
room temperature (RT) and stained with different anti-
bodies (see “Immunocytochemistry”).
BrdU incorporation
The proliferation of NSC was identified by in vitro label-
ing with the thymidine analog 5-bromo-2-desoxyuridine
(BrdU; Wako, Japan, Cat-No: 023–15563). NSC spheres
were collected and plated on coated 8-well glass cover-slip
and incubated for 24 h. Each well had a final concentration
of 22.8x104 cells/ml cultured in MHM, containing EGF
and bFGF and without FBS. The cells were treated with
different concentration of MPH (0 nM, 1 nM, 10 nM,
100 nM). After 24 h, BrdU was added to each well to reach
a final concentration of 10 μM and incubated for 4 h at
RT. Before BrdU immunostaining, DNA was denatured
and the nucleus-membrane was broken by treating cells
with 2M HCL for 35 min at RT; afterward, cells were
rinsed with 1% phosphate buffer saline (PBS), followed by
treatment with sodium borate (pH=8.5) for 10 min at RT
for the neutralization of HCL. The prepared cells were
stained against BrdU (see “Immunocytochemistry”).
Immunocytochemistry
Fixed and prepared cells were stained for differentiation
studies with rabbit monoclonal antibody against glial
fibrillary acidic protein (GFAP; 1:200, Sigma aldrich, USA,
Cat-No: C4546) and/or with mouse monoclonal antibody
against β-tubulin III (Tuj 1; 1:300, Sigma aldrich, USA,
Cat-No: T3952) overnight at 4°C. For proliferation stud-
ies, cells were stained with rat monoclonal antibody
against BrdU (1:100, Accurate Chemical & Scientific,
Japan, Cat-No: OBT0030) overnight at 4°C. In both stud-
ies, fixed cells were also stained with Hoechst 33258
(1:100; Invitrogen, Cat-No: H3569) for 15 min at RT to
visualize the cell nuclei. After overnight incubation, the
primary antibodies were visualized with secondary anti-
bodies against rabbit, mouse, or rat conjugated to the
following fluorochromes: Alexa FluorW -488 and Alexa
FluorW -555 (Life Technologies, Japan).
Statistical analysis
The stainings were analyzed for the cell count of astrocytes,
immature neurons and proliferated cells in compari-
son to the total number of cells using the Mann–
Figure 1 Murine neural stem cell (mNSC) differentiation into immature neurons. A) mNSCs were treated with different concentration
(0 nM, 1 nM, 10 nM, 100 nM) of methylphenidate (MPH). The percentage (% control) of developed neurons was determined 4 days after treatment
with MPH. The amount of immature neurons was analyzed by counting the neuron-specific class III beta-tubulin (Tuj 1) positive cells in comparison to
the total number of cells by using the Mann–Whitney (U-Rang) Test; -– =p <0.05; n= 28; seven independent experiments and four wells/slide of each
concentration were evaluated. B) An example of an immunocytochemistry staining of Tuj 1 in a control sample (no MPH treatment). The white arrow
points to a Tuj 1 positive cell (green) and the white arrow points to a cell nucleus staining with Hoechst (blue); 40x magnification.
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Whitney (U-Rang) Test in the StatView software program
(Stat View 5.0. software, SAS Institute Inc. Cary, NC, USA).
A p-value < 0.05 was set as significant. There were at least
five independent experiments, and four wells per slide were
analyzed. In each case, the total amount of Hoechst
stained cells/well were manually counted, and afterward,
either BrdU positive, GFAP positive, or Tuj 1 positive cells
were counted and the percentage of positive cells to the
total amount was calculated. In the proliferation and
differentiation studies a comparison of the treated mNSC
to the control mNSC (MPH untreated) was done.
Results
After 1 nM MPH treatment, the neuronal differentiation
was significantly enhanced, and 53% more immature neu-
rons could be detected compared to untreated mNSCs
(Figure 1). After 10 nM of MPH, the enhancement of
neuronal differentiation was over 80%, but the highest
Figure 2 Murine neural stem cell (mNSC) proliferation. A) mNSCs were treated with different concentration (0 nM, 1 nM, 10 nM, 100 nM) of
methylphenidate (MPH). The percentage (% of control) of proliferated cells was determined 28 h after induction of neuronal proliferation and
MPH treatment. The amount of proliferating cells was analyzed by counting the Bromodeoxyurdine (BrdU) positive cells in comparison to the
total number of cells using the Mann–Whitney (U-Rang) Test; -– =p <0.05; n= 20; five independent experiments and four wells/slide of each
concentration were evaluated. B) An example of an immunocytochemistry staining of BrdU in a control sample (no MPH treatment). The white
arrow points to a BrdU positive cell (red) and the white arrow points to a BrdU negative cell (blue); 10x magnification.
Figure 3 Murine neural stem cell (mNSC) differentiation into astrocytes. A) mNSCs were treated with different concentration (0 nM, 1 nM,
10 nM, 100 nM) of methylphenidate (MPH). The percentage (% control) of developed neurons was determined 4 days after treatment with MPH.
The amount of astrocytes was analyzed by counting the glial fibrillary acidic protein (GFAP) positive cells in comparison to the total number of
cells using the Mann–Whitney (U-Rang) Test; -– =p <0.05; n= 28; seven independent experiments and four wells/slide of each concentration were
evaluated. B) An example of an immunocytochemistry staining of GFAP in a control sample (no MPH treatment). GFAP positive cell (red) and cell
nucleus staining with Hoechst (blue); 40x magnification.
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dose of MPH (100 nM) showed a reduction of 39%
(Figure 1). In contrast, all tested concentration (1-100 nM)
of MPH inhibited the proliferation of mNSC (Figure 2).
For neuronal maturation, it is important that the neural
stem cell stops proliferating and starts the outgrowth of
neuritis to develop into full neurons, which seems to be
enhanced by the concentration of 1 nM and 10 nM of
used MPH. In contrasts, MPH treatment at the given dose
range did not significant affect the development of astro-
cytes in comparison to untreated mNSC (Figure 3).
Availability of supporting data
Discussion
In this work, we presented the effects of low doses
(1-100 nM) MPH treatment at mNSC proliferation and
neuronal maturation. In 2010 we could already demon-
strate, that especially low doses of MPH have the strongest
impact on gene expression and cell proliferation in neur-
onal cell line culture [11]. Our results suggest that MPH
seems to support neuronal maturation in a specific range
and enhances the neuronal outcome. This hypothesis fits
the fact that children with ADHD have atypical or typical
but delayed maturation of the prefrontal cortex [12].
Structural imaging in ADHD provides evidence for a global
maturational delay based on reduced gray and white matter
volume and cortical thickness in ADHD relative to controls
through childhood and adolescence [13,14]. MPH seems to
balance this retardation of neuronal development, but the
mechanism of action is still not known and needs further
investigation [15]. However, few studies have addressed
the structural correlates of psychostimulant treatment.
Castellanos et al. (2002) found that prior treatment with
psychostimulants in children with ADHD was associated at
study entry with greater white matter lobar volumes relative
to stimulant-naive children with ADHD and volumes that
lie closer to the range of their typically developing counter-
parts, suggesting a neuroprotective effect [16]. An inde-
pendent study of 30 children with ADHD examining the
regions implicated in the pathogenesis of the disorder,
similarly, found that treatment with psychostimulants was
associated with a more normative volume of the caudate
and anterior cingulate cortex [17]. Additionally, the group
of Antonello Bonci (2010) recently showed that MPH can
influence neuronal plasticity in the amygdale and, thus, can
improve learning performance [18]. Within the inherent
limitations of a preliminary study, we find great influences
of MPH on neuronal maturation, which may prove
activity-dependent neuronal plasticity. However, one has
to take into account that this in vitro experiment did not
investigate any MPH influences on neurogenesis, which
can be another possible mechanism of action of MPH.
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